The pressure's on Novo's marketing force as FDA nod for liraglutide nears

Novo Nordisk ($NVO) may be nearing the regulatory finish line with an obesity-fighting dose of liraglutide, up for debate by the FDA's advisers this week. But as its struggling rivals can attest, when it comes to weight-loss drugs, approval isn't everything, and it'll be up to Novo's marketing machine to take it from there. More